Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.
作者信息
Siebert Amy E, Mast Alan E
机构信息
Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
出版信息
J Thromb Haemost. 2020 Sep;18(9):2083-2086. doi: 10.1111/jth.14995. Epub 2020 Jul 30.
Abstract
摘要
相似文献
1
Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.血小板抗凝蛋白：促凝细胞内血栓形成倾向的调节因子。
J Thromb Haemost. 2020 Sep;18(9):2083-2086. doi: 10.1111/jth.14995. Epub 2020 Jul 30.
2
Procoagulant platelets and the pathways leading to cell death.促凝血血小板与导致细胞死亡的途径。
Semin Thromb Hemost. 2015 Jun;41(4):405-12. doi: 10.1055/s-0034-1544002. Epub 2015 Apr 16.
3
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.碳酸酐酶抑制剂抑制血小板的促凝反应和体内血栓形成。
Platelets. 2020 Oct 2;31(7):853-859. doi: 10.1080/09537104.2019.1709632. Epub 2020 Jan 1.
4
Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.检测促凝血小板可深入了解肝素诱导的血小板减少症的发病机制并具有诊断潜力。
J Thromb Haemost. 2022 Apr;20(4):975-988. doi: 10.1111/jth.15650. Epub 2022 Feb 7.
5
Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.血液凝固及其抗凝途径调节：出血性和血栓性疾病的遗传发病机制。
J Intern Med. 2005 Mar;257(3):209-23. doi: 10.1111/j.1365-2796.2004.01444.x.
6
Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.工程化“三合一”水蛭素前药以降低出血风险：概念验证研究。
J Control Release. 2021 Oct 10;338:462-471. doi: 10.1016/j.jconrel.2021.08.058. Epub 2021 Sep 1.
7
Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis.促凝血小板：血栓形成中的生成、功能和治疗靶点。
Blood. 2017 Nov 16;130(20):2171-2179. doi: 10.1182/blood-2017-05-787259. Epub 2017 Sep 27.
8
Mast cell-derived heparin proteoglycans as a model for a local antithrombotic.肥大细胞衍生的肝素蛋白聚糖作为局部抗血栓形成的模型。
Semin Thromb Hemost. 2014 Nov;40(8):837-44. doi: 10.1055/s-0034-1395157. Epub 2014 Nov 13.
9
Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.全球血栓形成试验（GTT）可以检测止血的主要决定因素，包括血小板反应性、内源性纤维蛋白溶解和凝血酶生成潜力。
Thromb Res. 2014 May;133(5):919-26. doi: 10.1016/j.thromres.2014.02.018. Epub 2014 Feb 25.
10
[Anticoagulant therapy in cardiovascular diseases. I. Thrombus formation and anticoagulants].
Kardiol Pol. 1970;13(4):351-8.
引用本文的文献
1
Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice.血小板组织因子途径抑制剂-α可抑制小鼠心脏血栓形成和相关纤维化。
J Thromb Haemost. 2023 Mar;21(3):639-651. doi: 10.1016/j.jtha.2022.11.034. Epub 2022 Dec 22.
2
The contribution of TFPIα to the hemostatic response to injury in mice.TFPIα 对小鼠损伤止血反应的贡献。
J Thromb Haemost. 2021 Sep;19(9):2182-2192. doi: 10.1111/jth.15430. Epub 2021 Jul 14.
3
Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression.Tfpi 基因敲除小鼠的宫内致死性在中晚期妊娠时被血小板 TFPIα 过表达差异抑制。
J Thromb Haemost. 2021 Jun;19(6):1483-1492. doi: 10.1111/jth.15299. Epub 2021 Apr 12.
本文引用的文献
1
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.血小板蛋白 S 通过控制血栓中的凝血来限制静脉血栓形成倾向，但不限制动脉血栓形成倾向。
Blood. 2020 May 28;135(22):1969-1982. doi: 10.1182/blood.2019003630.
2
Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.针对蛋白酶神经氨酸 1（一种天然抗凝丝氨酸蛋白酶抑制剂），以控制出血并改善血友病的止血功能。
Blood. 2019 Nov 7;134(19):1632-1644. doi: 10.1182/blood.2019000281.
3
Association of TFPI polymorphisms rs8176592, rs10931292, and rs10153820 with venous thrombosis: A meta-analysis.组织因子途径抑制物（TFPI）基因多态性rs8176592、rs10931292和rs10153820与静脉血栓形成的相关性：一项荟萃分析。
Medicine (Baltimore). 2019 Mar;98(12):e14978. doi: 10.1097/MD.0000000000014978.
4
Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.组织因子途径抑制物-α在低促凝强度下单核细胞依赖的纤维蛋白形成中起抑制作用。
Thromb Haemost. 2018 Mar;118(3):502-513. doi: 10.1055/s-0038-1627453. Epub 2018 Feb 16.
5
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.抗凝蛋白 S 靶向因子 IXa 肝素结合外显子以预防血栓形成。
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):816-828. doi: 10.1161/ATVBAHA.117.310588. Epub 2018 Feb 1.
6
Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S.血浆及血小板组织因子途径抑制物、因子V和蛋白S的相关因素
Res Pract Thromb Haemost. 2018 Jan;2(1):93-104. doi: 10.1002/rth2.12058. Epub 2017 Dec 29.
7
TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.组织因子途径抑制物α（TFPIα）在凝血起始阶段与活化的因子Ⅴ（FVa）和活化的因子Ⅹ（FXa）相互作用，以抑制凝血酶原酶。
Blood Adv. 2017 Dec 26;1(27):2692-2702. doi: 10.1182/bloodadvances.2017011098.
8
Vitamin K-Dependent Protein S: Beyond the Protein C Pathway.维生素 K 依赖性蛋白 S：超越蛋白 C 途径。
Semin Thromb Hemost. 2018 Mar;44(2):176-184. doi: 10.1055/s-0037-1604092. Epub 2017 Sep 13.
9
The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg cleavage site.组织因子途径抑制物-α 的 C 末端通过保护 Arg 裂解位点来抑制因子 V 的激活。
J Thromb Haemost. 2017 Jan;15(1):140-149. doi: 10.1111/jth.13559. Epub 2016 Dec 3.
10
A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function.一种新型 F5 基因突变（因子 V 阿姆斯特丹突变）与因子 V 促凝功能无关的出血相关。
Blood. 2015 Mar 12;125(11):1822-5. doi: 10.1182/blood-2014-08-592733. Epub 2015 Jan 29.
Zotero 插件